- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03413852
Treatment of Cerebral Arteriovenous Malformations With SQUID Liquid Embolic Agent (CHOICE) (CHOICE)
Treatment of Cerebral Arteriovenous Malformations With SQUID Liquid Embolic Agent - The CHOICE Study A Non-interventional, Prospective, Single-arm, International, Multicenter Study
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Edegem, Belgium
- University Hospital Antwerp
-
-
-
-
-
Odense, Denmark
- Odense University Hospital
-
-
-
-
-
Bordeaux, France
- CHU Bordeaux
-
Brest, France
- CHU Brest
-
Bron, France
- Hospices Civils de Lyon
-
Le Kremlin-Bicêtre, France
- CHU Bicêtre
-
Nancy, France, 54000
- Hôpital Central
-
Paris, France, 75010
- Hôpital Lariboisière
-
Paris, France, 75019
- Fondation Ophtalmologique Adolphe de Rothschild
-
Reims, France, 51000
- Hôpital Maison Blanche
-
Rouen, France
- CHU Rouen
-
Saint-Étienne, France, 42000
- CHU DE SAINT-ETIENNE
-
Toulouse, France
- CHU Toulouse
-
-
-
-
-
Augsburg, Germany
- Zentralklinikum Augsburg
-
Bochum, Germany
- Klinikum der Ruhr-Universität Bochum, Knappschaftskrankenhaus
-
Freiburg, Germany, 79106
- Universitatsklinikum Freiburg
-
Heidelberg, Germany
- Universitätsklinikum Heidelberg
-
Munich, Germany
- Klinikum Großhadern
-
-
-
-
-
Monza, Italy
- San Gerardo Monza
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Patient planned for one or multiple embolization sessions using SQUID to achieve occlusion of a previously untreated bAVM.*
*Patients with a direct fistula or saccular/flow-related aneurysm previously treated with NBCA and/or coils may be included.
- Patient in whom the use of SQUID had been decided for an embolization alone or in association to neurosurgery or radiotherapy.
- Patient ≥18 years old.
- Patient or authorized representative dully informed and having no objection to the clinical data collection and medical file access. An informed consent form must be signed and dated whenever required by local legislation
Exclusion Criteria:
- Patient with bAVM not eligible for endovascular treatment.
Patient with bAVM previously treated by embolization with other devices (Liquid embolic agent, NBCA, particles, and coils).*
*Patients with a direct fistula or saccular / flow-related aneurysm previously treated with NBCA and/or coils may be included.
- Patient with bAVM previously treated with surgery or radiotherapy.
- Patient intended to undergo surgery and embolization during the same procedure at first embolization
Patient with multiple bAVM or bAVM associated with dural arteriovenous Fistula*.
*Patients with a direct fistula or saccular / flow-related aneurysm previously treated with NBCA and/or coils may be included.
- Patient presenting contra-indication to the use of SQUID according to the Instructions For Use.
- Intention to treat with any non-adhesive embolic liquid other than SQUID, or planned treatment with another non-adhesive embolic liquid over the course of the endovascular treatment phase.
- Patient planned for a total endovascular treatment phase duration exceeding 2 years.
- Patient participating in another clinical study evaluating another medical device, another procedure or a medication.
- Any condition or any situation that would prohibit the patient from coming to the investigational center for the follow-up as recommended by the study protocol between 3 and 6 months, or prohibit carrying out the telephone mRS assessments at 1 month after each embolization session and at 12 months after the end of the endovascular treatment phase.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
modified Rankin Score (mRS)
Time Frame: 3 to 6 months after the last embolisation session
|
mRS is a scale used to measure the degree of handicap or dependence in daily activities of people who have suffered a stroke or other causes of neurological handicap. The scale ranges from 0 to 6, running from perfect health, without symptoms, to death. 0 - No symptoms
|
3 to 6 months after the last embolisation session
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Cardiovascular Abnormalities
- Neoplasms, Vascular Tissue
- Nervous System Malformations
- Vascular Malformations
- Intracranial Arterial Diseases
- Central Nervous System Vascular Malformations
- Congenital Abnormalities
- Hemangioma
- Arteriovenous Malformations
- Intracranial Arteriovenous Malformations
Other Study ID Numbers
- CIP-201701-SQUID
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cerebral Arteriovenous Malformation
-
Centre hospitalier de l'Université de Montréal...Active, not recruitingUnruptured Brain Arteriovenous Malformation | Ruptured Brain Arteriovenous Malformation | Arteriovenous Malformations, CerebralCanada, France
-
Fondation Ophtalmologique Adolphe de RothschildNot yet recruiting
-
Microvention-Terumo, Inc.ClinSearchTerminatedCerebral AV MalformationUnited Kingdom, Spain, Denmark, France, Sweden
-
Seoul National University HospitalRecruitingBrain Neoplasms | Cerebral Aneurysm | Cerebral Arteriovenous Malformation | Navigation, SpatialKorea, Republic of
-
yuanli ZhaoPeking University International HospitalRecruitingCerebral Arteriovenous MalformationChina
-
Beijing Tiantan HospitalNot yet recruitingCerebral Arteriovenous MalformationChina
-
Medical University of ViennaMedical Scientific Fund of the Mayor of ViennaRecruitingCerebral Arteriovenous MalformationAustria
-
University Hospital, LimogesRecruitingCerebral Arterio-venous MalformationFrance
-
Beijing Tiantan HospitalUnknownLanguage | AVM - Cerebral Arteriovenous MalformationChina
-
Centre hospitalier de l'Université de Montréal...Centre Hospitalier Régional et Universitaire de BrestRecruitingArteriovenous Malformations | Unruptured Brain Arteriovenous Malformation | Ruptured Brain Arteriovenous Malformation | AVM | BAVMFrance, United States, Canada, Brazil, Chile, Colombia
Clinical Trials on SQUID non-adhesive liquid embolic agent
-
Dr. Markus Alfred MöhlenbruchUniversity Hospital Schleswig-HolsteinCompletedDural Arteriovenous FistulaGermany
-
Hospital Universitari Vall d'Hebron Research InstituteRecruitingChronic Subdural HematomaSpain